+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07500298

Study of SAR445877 Combined With FOLFOX6 and Bevacizumab as First Treatment for Microsatellite Stable Metastatic Colorectal Cancer

Led by M.D. Anderson Cancer Center · Updated on 2026-11-02

41

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the safety and effectiveness of SAR445877 combined with FOLFOX6 and bevacizumab as a first-line treatment for patients with advanced microsatellite stable MSS metastatic colorectal cancer CRC. The study aims to find the highest safe dose and recommended dose for future research while evaluating how well this combination works against the cancer. Participants will receive SAR445877, FOLFOX6, and bevacizumab through intravenous infusions. The study has two parts a dose escalation phase to find the maximum tolerated dose using a Bayesian design, followed by a dose expansion phase to further assess this dose. Treatment will be given as the initial therapy for metastatic CRC. During the study, participants will be closely monitored for safety and side effects for about one year. Researchers will assess tumor response using standardized criteria and check organ function through lab tests. Visits will include evaluations to track treatment effects and overall health until the study ends in 2032, with the primary focus on safety and adverse events.

CONDITIONS

Brief Title

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Research Team

A

Aung Naing, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here